Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IXORA-S: Ixekizumab vs Ustekinumab in Plaque Psoriasis
NCT02561806Phase 3Completed
- Sponsor
- Eli Lilly and Company
- Start
- Oct 2015
- Primary completion
- May 2016
- Modality
- Monoclonal Antibodies
- Countries
- 13
01
Overview
A Phase 3 trial of ixekizumab in plaque psoriasis, sponsored by Eli Lilly and Company. Started Oct 2015; status: completed.
02
Drugs
ixekizumab
03
Conditions
plaque psoriasis
Beyond the preview
Go deeper on NCT02561806.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02561806.